...
首页> 外文期刊>Journal of investigative medicine >Effects of Additive Therapy With Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy: Results of a Randomized, Placebo-Controlled, Double-Blind, Crossover Trial.
【24h】

Effects of Additive Therapy With Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy: Results of a Randomized, Placebo-Controlled, Double-Blind, Crossover Trial.

机译:螺内酯加成治疗对已经采用ACE抑制剂或ARB治疗的糖尿病患者蛋白尿的影响:一项随机,安慰剂对照,双盲,交叉试验的结果。

获取原文
获取原文并翻译 | 示例

摘要

INTRODUCTION:: Aldosterone seems to have deleterious effects on the kidneys. Many animal studies and a few clinical trials have shown that suppression of aldosteroneby aldosterone receptor blockers ameliorates these effects. METHOD:: In a double-blind crossover study, patients with diabetic nephropathy who were already receiving either angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) were given spironolactone or matching placebo with 1 month of washout in between. Blood pressure (BP), serum creatinine, serum potassium, and spot urine protein/creatinine were measured at the beginning and end of each study period. RESULTS:: Mean systolic BP on spironolactone went down from 153.64 (+/-25.95) at the beginning to 141.60 (+/-16.54) at the end of study (P = 0.01). Diastolic BP during spironolactone therapy did not change significantly. The urine protein/creatinine increased from 1.24 (+/-1.13) to 1.57 (+/-2.13) on placebo (P = 0.35) and decreased from 1.80 (+/-1.78) to 0.79(+/-0.99) during spironolactone therapy (P = 0.004). In other words proteinuria increased by 24% during the placebo treatment period but decreased by half (57%) during the active treatment. Serum potassium increased from 4.29 (+/-0.47) to 4.64 (+/-0.55) during spironolactone therapy (P = 0.002), no significant change with placebo. Whereas serum creatinine did not change on placebo, it increased from 1.35 (+/-0.54) to 1.56 (+/-0.62) on spironolactone (P = 0.006). Glomerular filtration rate decreased from 61.91 (+/-23.4) to 53.94 (+/-23.58) on spironolactone (P = 0.0001) but not on placebo. CONCLUSIONS:: Addition of a modest dose of spironolactone to a regimen of ACEI or ARB in patients with diabetic proteinuria causes further reduction in proteinuria and also lowers the systolic BP. As with ACEI or ARB, spironolactone modestly reduces the glomerular filtration rate and raises serum potassium.
机译:简介:醛固酮似乎对肾脏有有害作用。许多动物研究和一些临床试验表明,醛固酮受体阻滞剂抑制醛固酮可改善这些作用。方法:在一项双盲交叉研究中,已经接受血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)的糖尿病肾病患者接受了螺内酯或相匹配的安慰剂治疗,两者之间的清洗时间为1个月。在每个研究阶段的开始和结束时均测量血压(BP),血清肌酐,血清钾和尿蛋白/肌酐现货。结果:螺内酯的平均收缩压从研究开始时的153.64(+/- 25.95)降至研究结束时的141.60(+/- 16.54)(P = 0.01)。螺内酯治疗期间舒张压没有明显变化。螺内酯治疗期间,尿蛋白/肌酐从1.24(+/- 1.13)增加到1.57(+/- 2.13)(P = 0.35),从1.80(+/- 1.78)减少到0.79(+/- 0.99) (P = 0.004)。换句话说,蛋白尿在安慰剂治疗期间增加了24%,但在积极治疗期间减少了一半(57%)。螺内酯治疗期间血清钾从4.29(+/- 0.47)增加到4.64(+/- 0.55)(P = 0.002),安慰剂无明显变化。安慰剂组的血清肌酐没有变化,而螺内酯则从1.35(+/- 0.54)增加到1.56(+/- 0.62)(P = 0.006)。螺内酯(P = 0.0001)上的肾小球滤过率从61.91(+/- 23.4)降至53.94(+/- 23.58),而安慰剂则没有。结论:糖尿病性蛋白尿患者在ACEI或ARB方案中加适量螺内酯可导致蛋白尿进一步减少,并降低收缩压。与ACEI或ARB一样,螺内酯会适度降低肾小球滤过率并增加血清钾。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号